CAMBRIDGE, MA – October 21, 2025 – Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company pioneering therapies that target transcription factors, has announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the U.S. and Canada). The collaboration will evaluate FX-909, a first-in-class small molecule PPARG inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck’s anti–PD-1 immunotherapy, in a new cohort of an ongoing Phase 1 trial in metastatic urothelial cancer.
Science Significance
This collaboration underscores a major advance in transcription factor drug discovery, particularly in oncology, where FX-909 demonstrates both direct anti-tumor activity and immune modulation. FX-909 inhibits PPARG, a master regulator of luminal cancer cells, which helps drive immune evasion. By pairing this mechanism with KEYTRUDA’s PD-1 blockade, the trial aims to enhance T-cell activation and potentially overcome immunotherapy resistance, paving the way for a new generation of combination cancer treatments.
Regulatory Significance
The collaboration aligns with regulatory innovation trends encouraging mechanism-based combination trials in oncology. The Phase 1 study expansion, expected to begin enrollment in early 2026, will explore safety, tolerability, immunologic biomarkers, and preliminary efficacy of the combination. These outcomes will help inform a potential Phase 2 design and guide regulatory discussions with the U.S. FDA and global authorities for further clinical advancement in urothelial carcinoma and other solid tumors.
Business Significance
Advertisement
For Flare Therapeutics, this collaboration with Merck strengthens its clinical and strategic position in the immuno-oncology space. Partnering with a global leader like Merck, whose KEYTRUDA dominates the checkpoint inhibitor market, provides both credibility and access to critical clinical infrastructure. This alliance supports Flare’s growth trajectory, expands its pipeline visibility, and enhances investor confidence as the company progresses FX-909 and other transcription factor–based therapies.
Patients’ Significance
For patients with advanced or metastatic urothelial cancer, therapeutic options remain limited after resistance develops to existing immunotherapies. The combination of FX-909 and KEYTRUDA could offer a new therapeutic pathway, leveraging dual mechanisms to restore immune responsiveness and extend survival outcomes. If successful, this regimen could shift the treatment paradigm for bladder cancer and related malignancies, ultimately providing new hope for patients facing immune-resistant tumors.
Policy Significance
The collaboration reinforces the growing policy and industry emphasis on precision oncology and public-private partnerships to accelerate clinical innovation. It highlights the value of mechanism-driven collaborations between biotech innovators and established pharma leaders under the FDA’s evolving combination therapy guidance. These frameworks are designed to streamline development and reduce redundancy in clinical evaluations, ensuring faster patient access to novel treatments.
With FX-909 advancing as a first-in-class PPARG inhibitor and this new collaboration with Merck marking a pivotal milestone, Flare Therapeutics continues to expand its leadership in targeting transcription factors for cancer treatment. The planned Phase 1 combination study could set the foundation for future Phase 2 and 3 programs, potentially transforming the therapeutic landscape for urothelial carcinoma and beyond. This partnership exemplifies how science-driven alliances can accelerate the translation of cutting-edge discoveries into real-world patient benefit.
Source: Flare Therapeutics Inc. Press Release
